Website & contact details
- Website
- Group website
- The site of this company’s group or brand.
Oxford Nanoimaging Limited
- Incorporated
- 24 February 2016 (10 years)
- Industry
- Manufacture of optical precision instruments (26701)
- Directors
- Alex ParkerAlexander AravanisPaul Albert Scagnetti
- Accounts type
- Group
- Region
- South East
- Address
- Linacre House Jordan Hill Business ParkBanbury RoadOxfordOX2 8TA
Filing status
- Accounts due
- 31 December 2026
- Last accounts
- 31 December 2024
- Conf. stmt due
- 14 July 2027
- Last conf. stmt
- 30 June 2026
Charges
- Total
- 1
- Outstanding
- 1
- Part satisfied
- 0
- Satisfied
- 0
Officers 7 active
Officer details are public data from the Companies House register.
Parker, Alex, Dr
Director · Appointed 17 May 2025
American
Born November 1966
Aravanis, Alexander, Dr
Director · Appointed 3 November 2023
American
Born April 1975 (51)
Scagnetti, Paul
Secretary · Appointed 21 March 2023
Scagnetti, Paul Albert
Director · Appointed 8 March 2023
American
Born September 1967 (59)
Director · Appointed 20 December 2022
Also at Grey Wolf Therapeutics Limited · more companies
French
Born August 1966 (60)
Crandell, Keith Lawrence
Director · Appointed 21 December 2021
American
Born May 1960 (66)
Finn, Patrick John
Director · Appointed 15 December 2020
American
Born April 1971 (55)
Officer history (20 former)
27 May 2025
Resigned Mackay, Sean as Director
17 May 2025
Appointed Parker, Alex, Dr as Director
3 November 2023
Appointed Aravanis, Alexander, Dr as Director
3 November 2023
18 September 2023
Resigned Rodriguez, Shaun as Director
18 September 2023
Appointed Mackay, Sean as Director
30 May 2023
Resigned Jing, Bo as Director
21 March 2023
Resigned Jing, Bo as Secretary
21 March 2023
Appointed Scagnetti, Paul as Secretary
8 March 2023
Appointed Scagnetti, Paul Albert as Director
20 December 2022
12 December 2022
16 August 2022
Appointed Jing, Bo as Secretary
31 May 2022
Resigned Nisbet, Malcolm Alexander as Secretary
7 March 2022
Resigned Craig, Keith Robert as Director
7 March 2022
21 December 2021
Appointed Rodriguez, Shaun as Director
21 December 2021
Appointed Crandell, Keith Lawrence as Director
31 August 2021
31 August 2021
29 July 2021
Resigned Sickinghe, Jonkheer Feyo Joost as Secretary
29 July 2021
Appointed Nisbet, Malcolm Alexander as Secretary
15 December 2020
Appointed Finn, Patrick John as Director
18 November 2020
16 October 2020
10 April 2019
Appointed Sickinghe, Jonkheer Feyo Joost as Secretary
10 April 2019
Resigned Dobbs, Nick as Secretary
16 May 2018
16 May 2018
16 May 2018
17 April 2018
Resigned Witty, Andrew, Sir as Director
20 February 2018
Appointed Dobbs, Nick as Secretary
20 February 2018
Resigned Moffat, Kathryn Emma as Secretary
1 December 2017
Appointed Witty, Andrew, Sir as Director
17 October 2017
Appointed Moffat, Kathryn Emma as Secretary
17 October 2017
Resigned Humm, Roger James as Secretary
25 August 2017
Appointed Craig, Keith Robert as Director
13 July 2017
13 July 2017
Resigned Malloy, Andrew Paul as Director
6 June 2017
24 May 2016
Appointed Malloy, Andrew Paul as Director
29 April 2016
29 April 2016
Appointed Jing, Bo as Director
29 April 2016
29 April 2016
24 February 2016
24 February 2016
Appointed Humm, Roger James as Secretary
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 5 May 2016
Owns 25–50% of shares
Holds 25–50% of voting rights
Company
Reg. no. 09093331
Group structure 18 shown
Ownership group derived from the Companies House PSC register
Acionna Therapeutics Ltd Owns 50–75% of shares
Animal Dynamics Limited Owns 50–75% of shares
Archangel Lightworks Ltd Owns 25–50% of shares
Ascension Earth Resources Ltd Owns 25–50% of shares
Caudal Energy Limited Owns 25–50% of shares
Caudal Morlais Limited Owns 75–100% of shares
Circadian Therapeutics Limited Owns 75–100% of shares
Cora Biosciences Limited Owns 25–50% of shares
Credo Therapies Ltd Owns 50–75% of shares
Densix Limited Owns 25–50% of shares
Dyna Therapeutics Limited Owns 50–75% of shares
Eligentis Limited Owns 25–50% of shares
Evox Therapeutics Limited Owns 25–50% of shares
Fluorok Limited Owns 25–50% of shares
Oxford Nanoimaging Limited This company Owns 25–50% of shares
Financials
Balance sheet as at 31 December 2024 · group accounts
- Net Assets
- £23,320,363
- Cash
- £12,687,531
- Profit
- (£9,585,327)
- Employees
- 52
- Debt Ratio
- 24%
- Current Ratio
- 4.2x
- Return on Equity
- -41%
Trend
Net Assets
Balance sheet detail
| 2024 | 2023 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fixed Assets | £1,011,035 | £1,196,809 | £1,892,128 | £1,770,724 | £2,261,581 |
| Current Assets | £29,723,493 | £33,605,692 | £59,873,608 | £9,649,949 | £8,595,379 |
| Cash | £12,687,531 | £27,642,185 | £54,599,840 | £5,103,712 | £3,897,944 |
| Creditors (< 1 year) | £7,048,333 | £2,617,844 | £3,261,383 | £2,227,709 | £2,259,555 |
| Creditors (> 1 year) | £254,932 | £234,330 | £254,015 | ||
| Net Current Assets | £22,675,160 | £30,987,848 | £56,612,225 | £7,422,240 | £6,335,824 |
| Net Assets | £23,320,363 | £8,707,718 | £8,182,742 | ||
| Shareholder Funds | £23,320,363 | £31,836,540 | £57,928,997 | £8,707,718 | £8,182,742 |
Filings 123
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 8 September 2026 | Confirmation statement with updates | 30 June 2026 | ||
| 13 July 2026 | Statement of capital following an allotment of shares | |||
| 16 January 2026 | Change of details for a person with significant control | |||
| 22 December 2025 | Group of companies' accounts | 31 December 2024 | ||
| 2 December 2025 | Second filing for the appointment of a director |
Other companies in this industry
Southampton
Cambridge
Hamble Southampton
Hemel Hempstead
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →